Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-G79D in r/r SLE and r/r IIM
NCT07331272Phase 1Recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-G79D in systemic lupus erythematosus (SLE) and idiopathic inflammatory myopathy (IIM), sponsored by Legend Biotech Corporation. Primary endpoints: Treatment-Emergent Adverse Events at 104 weeks, Dose-Limiting Toxicity at 104 weeks and 4 more. Started Jan 2026; status: recruiting.
02
Drugs
LUCAR-G79D
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07331272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331272.